Chordate Medical’s Ozilia treatment system is currently used at nine clinics in Jeddah and Riyadh in Saudi Arabia for the treatment of chronic nasal congestion (rhinitis). In September 2024, Ozilia was also approved for the treatment of migraine by the Saudi Food and Drug Authority (SFDA).
To strengthen the establishment of migraine treatment, Chordate Medical has appointed Narro Trading Est. (Narro Medical) as a non-exclusive distributor in Saudi Arabia.
The fact that the company is now tying up with an additional distributor signals an increased focus on the neurology area and improves the opportunities to broaden its presence in the Saudi Arabian market.
– We already have a distributor in Saudi Arabia, but we see a need to increase focus and expertise in the neurology field. Narro Medical fits well into that strategy and is currently in the final stages of the qualification process, says Anders Weilandt, CEO of Chordate Medical.
– This includes demonstrating effective sales activities in the field, taking over the work with prospective customers we have previously engaged, and placing qualifying orders for demo equipment and stock – something they have successfully accomplished so far.
Comments from the CEO
BioStock contacted Anders Weilandt to find out more about the new distributor and the company’s marketing plans.
Why have you chosen to hire another distributor?
– Saudi Arabia is a large and dynamic market, but the range of distributors with a professional therapy focus is relatively underdeveloped. We have noted that we should be able to improve our focus on migraine with a market partner with a better defined focus.
How far have you come with Ozilia on the Saudi Arabian market?
– Although we have several installations in the rhinitis area already and are currently working on a list of potential customers for both indications, we have only just begun to exploit the market potential. There are about 500 hospitals, of which about 170 are private. We have regulatory product approval and Ozilia can be used in public hospitals according to a decision by the Ministry of Health. On the private side, there are compensation decisions from the largest insurance companies, including Bupa Arabia and Tawuniya. Relative to our starting point, we have considerable potential for further processing.
What are the plans to expand further in the Middle East?
– The plan is simple. We have no problem finding new potential customers who want a product demonstration and then a shorter trial period with our own patients. It is ordinary sales work, and the focus is simply on working as quickly as possible.
Innehållet i BioStocks nyheter och analyser är oberoende men BioStocks verksamhet är i viss mån finansierad av bolag i branschen. Detta inlägg avser ett bolag som BioStock erhållit finansiering från.
